JP2005526011A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526011A5
JP2005526011A5 JP2003552709A JP2003552709A JP2005526011A5 JP 2005526011 A5 JP2005526011 A5 JP 2005526011A5 JP 2003552709 A JP2003552709 A JP 2003552709A JP 2003552709 A JP2003552709 A JP 2003552709A JP 2005526011 A5 JP2005526011 A5 JP 2005526011A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
acceptable salt
oxoethoxy
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003552709A
Other languages
English (en)
Japanese (ja)
Other versions
JP3784804B2 (ja
JP2005526011A (ja
Filing date
Publication date
Priority claimed from SE0104334A external-priority patent/SE0104334D0/xx
Application filed filed Critical
Publication of JP2005526011A publication Critical patent/JP2005526011A/ja
Publication of JP2005526011A5 publication Critical patent/JP2005526011A5/ja
Application granted granted Critical
Publication of JP3784804B2 publication Critical patent/JP3784804B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003552709A 2001-12-19 2002-12-18 ヒトのペルオキシソーム増殖因子活性化受容体α(PPAR)に対するアゴニストとしての置換フェニルプロピオン酸誘導体 Expired - Fee Related JP3784804B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104334A SE0104334D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005738 WO2003051821A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005235794A Division JP2005336209A (ja) 2001-12-19 2005-08-16 ヒトのペルオキシソーム増殖因子活性化受容体α(PPAR)に対するアゴニストとしての置換フェニルプロピオン酸誘導体

Publications (3)

Publication Number Publication Date
JP2005526011A JP2005526011A (ja) 2005-09-02
JP2005526011A5 true JP2005526011A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP3784804B2 JP3784804B2 (ja) 2006-06-14

Family

ID=20286433

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003552709A Expired - Fee Related JP3784804B2 (ja) 2001-12-19 2002-12-18 ヒトのペルオキシソーム増殖因子活性化受容体α(PPAR)に対するアゴニストとしての置換フェニルプロピオン酸誘導体
JP2003552710A Expired - Lifetime JP3820249B2 (ja) 2001-12-19 2002-12-18 ヒトペルオキソーム増殖因子活性化受容体α(PPAR)のアゴニストである置換フェニルプロピオン酸誘導体
JP2005235794A Pending JP2005336209A (ja) 2001-12-19 2005-08-16 ヒトのペルオキシソーム増殖因子活性化受容体α(PPAR)に対するアゴニストとしての置換フェニルプロピオン酸誘導体
JP2006123399A Pending JP2006298924A (ja) 2001-12-19 2006-04-27 置換フェニルプロピオン酸誘導体を含む医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2003552710A Expired - Lifetime JP3820249B2 (ja) 2001-12-19 2002-12-18 ヒトペルオキソーム増殖因子活性化受容体α(PPAR)のアゴニストである置換フェニルプロピオン酸誘導体
JP2005235794A Pending JP2005336209A (ja) 2001-12-19 2005-08-16 ヒトのペルオキシソーム増殖因子活性化受容体α(PPAR)に対するアゴニストとしての置換フェニルプロピオン酸誘導体
JP2006123399A Pending JP2006298924A (ja) 2001-12-19 2006-04-27 置換フェニルプロピオン酸誘導体を含む医薬組成物

Country Status (30)

Country Link
US (2) US7256307B2 (cg-RX-API-DMAC7.html)
EP (2) EP1458672B1 (cg-RX-API-DMAC7.html)
JP (4) JP3784804B2 (cg-RX-API-DMAC7.html)
KR (2) KR20040074092A (cg-RX-API-DMAC7.html)
CN (3) CN100406427C (cg-RX-API-DMAC7.html)
AR (2) AR038045A1 (cg-RX-API-DMAC7.html)
AT (2) ATE338743T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002366315A1 (cg-RX-API-DMAC7.html)
BR (2) BR0214988A (cg-RX-API-DMAC7.html)
CA (2) CA2470491A1 (cg-RX-API-DMAC7.html)
CY (2) CY1106276T1 (cg-RX-API-DMAC7.html)
DE (2) DE60214594T2 (cg-RX-API-DMAC7.html)
DK (2) DK1458672T3 (cg-RX-API-DMAC7.html)
ES (2) ES2271381T3 (cg-RX-API-DMAC7.html)
HU (2) HUP0402022A3 (cg-RX-API-DMAC7.html)
IL (3) IL162330A0 (cg-RX-API-DMAC7.html)
IS (2) IS7309A (cg-RX-API-DMAC7.html)
MX (2) MXPA04006004A (cg-RX-API-DMAC7.html)
MY (1) MY132565A (cg-RX-API-DMAC7.html)
NO (2) NO20043023L (cg-RX-API-DMAC7.html)
NZ (2) NZ533274A (cg-RX-API-DMAC7.html)
PL (2) PL370672A1 (cg-RX-API-DMAC7.html)
PT (2) PT1458673E (cg-RX-API-DMAC7.html)
RU (2) RU2303031C2 (cg-RX-API-DMAC7.html)
SE (1) SE0104334D0 (cg-RX-API-DMAC7.html)
SI (2) SI1458672T1 (cg-RX-API-DMAC7.html)
TW (2) TWI253444B (cg-RX-API-DMAC7.html)
UA (2) UA77460C2 (cg-RX-API-DMAC7.html)
WO (2) WO2003051821A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA200404657B (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) * 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
CN1662487A (zh) * 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
CA2489834C (en) 2002-06-20 2006-10-03 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
CA2549008A1 (en) * 2003-12-15 2005-07-07 Eli Lilly And Company Selective peroxisome proliferator activated receptor modulators
MX2007001634A (es) 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
SE0403072D0 (sv) * 2004-12-16 2004-12-16 Astrazeneca Ab Pharmaceutically useful salts of carboxylic acid derivates
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
TWI331523B (en) * 2005-12-08 2010-10-11 Nat Health Research Institutes Vinylsulfonate compounds
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
JO3301B1 (ar) * 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CA3011595C (en) 2016-02-09 2024-01-02 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2023039276A1 (en) * 2021-09-13 2023-03-16 Curtails Llc Use of ibat inhibitors and antimicrobials for the treatment of diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266121C (cg-RX-API-DMAC7.html)
BE489216A (cg-RX-API-DMAC7.html) 1948-06-05 1900-01-01
US2928840A (en) * 1958-11-26 1960-03-15 Us Vitamin Pharm Corp 3-(o-substituted phenyl) oxazolidinediones and process therefor
GB1081471A (en) 1963-09-13 1967-08-31 Stauffer Chemical Co Glycol amide derivatives and use thereof in controlling weed growth
US3244398A (en) * 1963-10-28 1966-04-05 Scaramucci Domer Composite seat ball valve
AT307640B (de) 1970-06-18 1973-05-25 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen
BE792364A (fr) 1971-12-06 1973-06-06 Basf Ag Derives de substitution du sulfonylglycolanilide
DE2349256C2 (de) 1973-10-01 1985-08-01 Basf Ag, 6700 Ludwigshafen 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide
DE2828222A1 (de) 1978-06-28 1980-01-10 Bayer Ag Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide
US4735959A (en) * 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US5312924A (en) * 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5216167A (en) * 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5210208A (en) * 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
US6410585B1 (en) * 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
AU749132B2 (en) 1997-08-28 2002-06-20 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
AU1457299A (en) 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
PL351898A1 (en) 1999-04-06 2003-06-30 Sankyo Co O-substituted derivatives of carboxylic acids
AU3670900A (en) * 1999-04-08 2000-11-14 Sankyo Company Limited Substituted fused imidazole derivatives
AU4139600A (en) 1999-04-14 2000-11-14 University Of British Columbia, The 1,3-dipolar cycloadditions to polypyrrolic macrocycles
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001261612A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
AU2002222552A1 (en) 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
AU2002222550A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
WO2002083616A1 (en) 2001-04-10 2002-10-24 Sankyo Company, Limited α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Similar Documents

Publication Publication Date Title
RU2379295C2 (ru) Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
JPH11302257A5 (cg-RX-API-DMAC7.html)
JP2010521514A5 (cg-RX-API-DMAC7.html)
JP2004517813A5 (cg-RX-API-DMAC7.html)
JP2012506896A5 (cg-RX-API-DMAC7.html)
JP2004509128A5 (cg-RX-API-DMAC7.html)
RU2007119378A (ru) Твердый состав с улучшенными растворимостью и стабильностью и способ его получения
JP2005053931A5 (cg-RX-API-DMAC7.html)
JP2004507519A5 (cg-RX-API-DMAC7.html)
JP2011520815A5 (cg-RX-API-DMAC7.html)
JP2006509749A5 (cg-RX-API-DMAC7.html)
JP2002501041A5 (cg-RX-API-DMAC7.html)
JP2007534702A5 (cg-RX-API-DMAC7.html)
JP2012510502A5 (cg-RX-API-DMAC7.html)
JP2010090149A5 (cg-RX-API-DMAC7.html)
JP2008512470A5 (cg-RX-API-DMAC7.html)
JP2013517322A5 (cg-RX-API-DMAC7.html)
JP2005530852A5 (cg-RX-API-DMAC7.html)
JP2010526801A5 (cg-RX-API-DMAC7.html)
JP2009539822A5 (cg-RX-API-DMAC7.html)
JP2009504793A5 (cg-RX-API-DMAC7.html)
JP2004529172A5 (cg-RX-API-DMAC7.html)
JP2008533063A5 (cg-RX-API-DMAC7.html)
JP2013504592A5 (cg-RX-API-DMAC7.html)
JP2012522840A5 (cg-RX-API-DMAC7.html)